BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:XYone Therapeutics\, Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies XYone Therapeutics\, Inc's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07670312-2811@assetmemo.bio
DTSTAMP:20261121T005949Z
DTSTART;VALUE=DATE:20290915
DTEND;VALUE=DATE:20290916
SUMMARY:XYA02: Phase 1/2 readout est. (NCT07670312)
DESCRIPTION:XYA02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Evaluat
 ion of XYA02 in Patients With Advanced Solid Tumors\nEstimated primary com
 pletion: 15 September 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/xya02#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07670312
URL:https://assetmemo.bio/drug/xya02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
